“
TL;DR
The paper is a narrative review discussing polypharmacology, a strategy for designing or using pharmaceutical agents that act on multiple targets or disease pathways.
Pharmacological Reports · 3 authors, 2 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
The paper is a narrative review discussing polypharmacology, a strategy for designing or using pharmaceutical agents that act on multiple targets or disease pathways.
The paper is a narrative review discussing polypharmacology, a strategy for designing or using pharmaceutical agents that act on multiple targets or disease pathways. The authors surveyed 49 drugs introduced in Germany in 2022 and identified 10 as MTDLs. These include seven antitumor agents (e.g., ripretinib, trastuzumab deruxtecan, tebentafusp), two drugs for brain disorders (including daridorexant, an orexin receptor antagonist), and one for age-related macular degeneration (faricimab). The review highlights polypharmacology as a response to challenges like multifactorial diseases and drug resistance. Limitations include its nature as a conceptual overview without original clinical data generation or analysis. The implications are that polypharmacology represents a growing approach in drug design, with several new MTDLs entering the therapeutic armamentarium.